CN114729022A - 缀合的铁调素模拟物 - Google Patents

缀合的铁调素模拟物 Download PDF

Info

Publication number
CN114729022A
CN114729022A CN202080076351.4A CN202080076351A CN114729022A CN 114729022 A CN114729022 A CN 114729022A CN 202080076351 A CN202080076351 A CN 202080076351A CN 114729022 A CN114729022 A CN 114729022A
Authority
CN
China
Prior art keywords
seq
hepcidin
pharmaceutically acceptable
subject
isovaleric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080076351.4A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·Y·刘
格雷戈里·托马斯·伯恩
鲁帕·塔拉纳特
苏尼尔·库马尔·古普塔
尼希特·巴楚拉尔·莫迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of CN114729022A publication Critical patent/CN114729022A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080076351.4A 2019-09-03 2020-09-03 缀合的铁调素模拟物 Pending CN114729022A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962895201P 2019-09-03 2019-09-03
US62/895,201 2019-09-03
US202062983515P 2020-02-28 2020-02-28
US62/983,515 2020-02-28
US202063020945P 2020-05-06 2020-05-06
US63/020,945 2020-05-06
US202063059747P 2020-07-31 2020-07-31
US63/059,747 2020-07-31
PCT/US2020/049244 WO2021046246A1 (en) 2019-09-03 2020-09-03 Conjugated hepcidin mimetics

Publications (1)

Publication Number Publication Date
CN114729022A true CN114729022A (zh) 2022-07-08

Family

ID=74681239

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080076351.4A Pending CN114729022A (zh) 2019-09-03 2020-09-03 缀合的铁调素模拟物

Country Status (16)

Country Link
US (2) US20220372099A1 (enExample)
EP (2) EP4706671A3 (enExample)
JP (2) JP7831841B2 (enExample)
KR (1) KR20220075343A (enExample)
CN (1) CN114729022A (enExample)
AU (2) AU2020343328B2 (enExample)
BR (1) BR112022003999A2 (enExample)
CA (1) CA3152789A1 (enExample)
DK (1) DK4025592T3 (enExample)
ES (1) ES3058577T3 (enExample)
FI (1) FI4025592T3 (enExample)
IL (1) IL291030A (enExample)
MX (1) MX2022002633A (enExample)
PH (1) PH12022550510A1 (enExample)
PL (1) PL4025592T3 (enExample)
WO (1) WO2021046246A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
WO2022212696A1 (en) * 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3220871A1 (en) * 2021-06-14 2022-12-22 Protagonist Therapeutics, Inc. Hepcidin mimetics for treatment of hereditary hemochromatosis
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
US20250170216A1 (en) * 2022-02-02 2025-05-29 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
WO2024011188A1 (en) * 2022-07-07 2024-01-11 Protagonist Therapeutics, Inc. Combination therapy for treatment of iron overload diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075574A (zh) * 2014-06-27 2017-08-18 领导医疗有限公司 铁调素和微型铁调素类似物及其用途
WO2019157268A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
US7094785B1 (en) * 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
KR20170002414A (ko) * 2014-04-07 2017-01-06 멀겐져 바이오텍, 아이엔씨. 헵시딘 모방 펩티드 및 그 용도
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
CA3009834A1 (en) * 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
AU2017324446A1 (en) 2016-09-06 2019-03-28 La Jolla Pharmceutical Company Methods of treating iron overload
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075574A (zh) * 2014-06-27 2017-08-18 领导医疗有限公司 铁调素和微型铁调素类似物及其用途
WO2019157268A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Also Published As

Publication number Publication date
JP7831841B2 (ja) 2026-03-17
AU2026205090A1 (en) 2026-07-16
FI4025592T3 (fi) 2026-01-30
US20220372099A1 (en) 2022-11-24
US20210061872A1 (en) 2021-03-04
JP2025163134A (ja) 2025-10-28
MX2022002633A (es) 2022-06-02
EP4706671A2 (en) 2026-03-11
AU2020343328A1 (en) 2022-04-07
EP4706671A3 (en) 2026-04-01
KR20220075343A (ko) 2022-06-08
PH12022550510A1 (en) 2023-09-04
JP2022546878A (ja) 2022-11-09
DK4025592T3 (da) 2026-02-09
ES3058577T3 (en) 2026-03-11
EP4025592A1 (en) 2022-07-13
EP4025592B1 (en) 2025-10-29
PL4025592T3 (pl) 2026-03-16
WO2021046246A1 (en) 2021-03-11
IL291030A (en) 2022-05-01
AU2020343328B2 (en) 2026-04-09
CA3152789A1 (en) 2021-03-11
BR112022003999A2 (pt) 2022-05-31
EP4025592A4 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
EP4025592B1 (en) Conjugated hepcidin mimetics for use in treating of polycythemia vera
US12269856B2 (en) Hepcidin analogues and uses thereof
US12234300B2 (en) Conjugated hepcidin mimetics
US20210147483A1 (en) Analogues of hepcidin mimetics with improved in vivo half lifes
JP2026048851A (ja) コンジュゲートされたヘプシジン模倣物
KR20170043509A (ko) 헵시딘 및 미니-헵시딘 유사체 및 그의 용도
TW202304951A (zh) 結合鐵調素模擬物
WO2022212698A1 (en) Conjugated hepcidin mimetics
EA048412B1 (ru) Конъюгированные миметики гепсидина
CN116457000A (zh) 缀合的铁调素模拟物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination